Article Text
Commentary
General medicine
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV
1
than long-acting beta-agonists plus inhaled corticosteroids
Statistics from Altmetric.com
Footnotes
Competing interests MC and PR are consultants and/or members of the Speaker Bureau at AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and Novartis.
Provenance and peer review Commissioned; internally peer reviewed.